242 related articles for article (PubMed ID: 33288604)
1. Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer.
Fujii H; Makiyama A; Iihara H; Okumura N; Yamamoto S; Imai T; Arakawa S; Kobayashi R; Tanaka Y; Yoshida K; Suzuki A
Anticancer Res; 2020 Dec; 40(12):7067-7075. PubMed ID: 33288604
[TBL] [Abstract][Full Text] [Related]
2. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses.
Matsumoto T; Yamamoto Y; Kuriona Y; Okazaki U; Kimura S; Miura K; Tsuduki T; Watanabe T; Mastumoto Y; Takatani M
BMC Cancer; 2020 Jul; 20(1):684. PubMed ID: 32698781
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors.
Takemura K; Yuasa T; Fujiwara R; Ito M; Suzuki H; Yonese J; Koga F
J Urol; 2020 Dec; 204(6):1166-1172. PubMed ID: 32567459
[TBL] [Abstract][Full Text] [Related]
6. Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.
Sano A; Sohda M; Nakazawa N; Ubukata Y; Kuriyama K; Kimura A; Kogure N; Hosaka H; Naganuma A; Sekiguchi M; Saito K; Ogata K; Sakai M; Ogawa H; Shirabe K; Saeki H
BMC Cancer; 2022 Jan; 22(1):22. PubMed ID: 34980017
[TBL] [Abstract][Full Text] [Related]
7. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).
Kato K; Satoh T; Muro K; Yoshikawa T; Tamura T; Hamamoto Y; Chin K; Minashi K; Tsuda M; Yamaguchi K; Machida N; Esaki T; Goto M; Komatsu Y; Nakajima TE; Sugimoto N; Yoshida K; Oki E; Nishina T; Tsuji A; Fujii H; Kunieda K; Saitoh S; Omuro Y; Azuma M; Iwamoto Y; Taku K; Fushida S; Chen LT; Kang YK; Boku N
Gastric Cancer; 2019 Mar; 22(2):344-354. PubMed ID: 30506519
[TBL] [Abstract][Full Text] [Related]
8. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Mishima S; Kawazoe A; Nakamura Y; Sasaki A; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Tsuji A; Shitara K
J Immunother Cancer; 2019 Jan; 7(1):24. PubMed ID: 30704511
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Nishiyama T; Chen LT; Kang YK
Gastric Cancer; 2021 Jul; 24(4):946-958. PubMed ID: 33743112
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
13. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.
Yamada T; Hayashi T; Inokuchi Y; Hayashi K; Watanabe H; Komori K; Kano K; Shimoda Y; Fujikawa H; Shiozawa M; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
Target Oncol; 2020 Jun; 15(3):317-325. PubMed ID: 32319020
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden.
Suzuki H; Yamada T; Sugaya A; Ueyama S; Yamamoto Y; Moriwaki T; Hyodo I
Int J Clin Oncol; 2021 Feb; 26(2):370-377. PubMed ID: 33090284
[TBL] [Abstract][Full Text] [Related]
17. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.
Abe K; Shibata K; Naito T; Otsuka A; Karayama M; Maekawa M; Miyake H; Suda T; Kawakami J
Eur J Clin Pharmacol; 2022 Jan; 78(1):77-87. PubMed ID: 34410448
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Evaluation of the Efficacy and Adverse Effects of Nivolumab Treatment for Patients with Advanced Gastric Cancer].
Ohta A; Komatsu S; Tsuji R; Tanaka S; Kumano T; Imura K; Shimomura K; Ikeda J; Taniguchi F; Doi T; Yamada S; Tomatsuri N; Yoshida N; Shioaki Y
Gan To Kagaku Ryoho; 2020 Apr; 47(4):725-727. PubMed ID: 32389997
[TBL] [Abstract][Full Text] [Related]
19. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
[TBL] [Abstract][Full Text] [Related]
20. Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab.
Kono Y; Choda Y; Nakagawa M; Miyahara K; Ishida M; Kubota T; Seo K; Hirata T; Obayashi Y; Gotoda T; Moritou Y; Okikawa Y; Iwamoto Y; Okada H
Target Oncol; 2021 Mar; 16(2):237-248. PubMed ID: 33475927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
